Involvement of LTB4 in zymosan-induced joint nociception in mice: participation of neutrophils and PGE2
- 3 October 2007
- journal article
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 83 (1) , 122-130
- https://doi.org/10.1189/jlb.0207123
Abstract
Leukotriene B4 (LTB4) mediates different inflammatory events such as neutrophil migration and pain. The present study addressed the mechanisms of LTB4-mediated joint inflammation-induced hypernociception. It was observed that zymosan-induced articular hypernociception and neutrophil migration were reduced dose-dependently by the pretreatment with MK886 (1–9 mg/kg; LT synthesis inhibitor) as well as in 5-lypoxygenase-deficient mice (5LO−/−) or by the selective antagonist of the LTB4 receptor (CP105696; 3 mg/kg). Histological analysis showed reduced zymosan-induced articular inflammatory damage in 5LO−/− mice. The hypernociceptive role of LTB4 was confirmed further by the demonstration that joint injection of LTB4 induces a dose (8.3, 25, and 75 ng)-dependent articular hypernociception. Furthermore, zymosan induced an increase in joint LTB4 production. Investigating the mechanism underlying LTB4 mediation of zymosan-induced hypernociception, LTB4-induced hypernociception was reduced by indomethacin (5 mg/kg), MK886 (3 mg/kg), celecoxib (10 mg/kg), antineutrophil antibody (100 μg, two doses), and fucoidan (20 mg/kg) treatments as well as in 5LO−/− mice. The production of LTB4 induced by zymosan in the joint was reduced by the pretreatment with fucoidan or antineutrophil antibody as well as the production of PGE2 induced by LTB4. Therefore, besides reinforcing the role of endogenous LTB4 as an important mediator of inflamed joint hypernociception, these results also suggested that the mechanism of LTB4-induced articular hypernociception depends on prostanoid and neutrophil recruitment. Furthermore, the results also demonstrated clearly that LTB4-induced hypernociception depends on the additional release of endogenous LTs. Concluding, targeting LTB4 synthesis/action might constitute useful therapeutic approaches to inhibit articular inflammatory hypernociception.Keywords
Funding Information
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Conselho Nacional de Pesquisa
- Coordenadoria de Aperfeiçoamento de Pessoal de Nível Superior
This publication has 48 references indexed in Scilit:
- Clinical trial of a leucotriene B4 receptor antagonist, BIIL 284, in patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 2007
- Neutrophil recruitment in immunized mice depends on MIP-2 inducing the sequential release of MIP-1α, TNF-α and LTB4European Journal of Immunology, 2006
- ANTI-INFLAMMATORY AND ANTI-NOCICEPTIVE ACTIVITY OF RISEDRONATE IN EXPERIMENTAL PAIN MODELS IN RATS AND MICEClinical and Experimental Pharmacology and Physiology, 2006
- IL-15 mediates immune inflammatory hypernociception by triggering a sequential release of IFN-γ, endothelin, and prostaglandinProceedings of the National Academy of Sciences, 2006
- A unique requirement for the leukotriene B4 receptor BLT1 for neutrophil recruitment in inflammatory arthritisThe Journal of Experimental Medicine, 2006
- (+)-1-(3S,4R)-[3-(4-Phenylbenzyl)-4- hydroxychroman-7-yl]cyclopentane Carboxylic Acid, a Highly Potent, Selective Leukotriene B4 Antagonist with Oral Activity in the Murine Collagen-Induced Arthritis ModelJournal of Medicinal Chemistry, 1994
- Leukotriene B4 stimulation of macrophage cyclooxygenase metabolite synthesisInflammation Research, 1991
- Rheumatoid ArthritisNew England Journal of Medicine, 1990
- Effects of sucralfate on gastric prostaglandin and leukotriene synthesis: relationship to protective actionsCanadian Journal of Physiology and Pharmacology, 1988
- Lipoxygenation of arachidonic acid as a source of polymorphonuclear leukocyte chemotactic factors in synovial fluid and tissue in rheumatoid arthritis and spondyloarthritis.Journal of Clinical Investigation, 1980